Axon Stock Plummets 18%: Is This a Golden Buying Opportunity?

Axon Enterprise (AXON) reported third-quarter earnings on Friday that sent its stock tumbling 18% to a two-year low. The company posted revenue of $908.6 million, up 28% year-over-year but below the consensus estimate of $934.3 million. More concerning for investors, Axon's fourth-quarter revenue guidance of $990 million to $1.01 billion came in well below the $1.07 billion consensus, representing its slowest growth since 2021.

The revenue miss was primarily due to a timing issue: a $30 million Federal Dedrone deployment that was expected to be recognized in Q3 was delayed. Had that revenue been booked, Axon would have met revenue estimates. However, the delayed deployment also pushed $100 million of expected Q4 federal Dedrone revenue out of the guidance, contributing to the weak outlook.

Additionally, Axon cut its full-year free cash flow guidance from $450 million to $350 million-$400 million, citing accelerated inventory growth to improve product availability and supply chain resilience. The company also reported a decline in legacy Taser sales, down 2% year-over-year, and a drop in adjusted gross margin from 52.1% to 44.6% due to a higher mix of counter-drone equipment and increased memory costs.

Several analysts weighed in: Piper Sandler noted that gross margin in the products division fell below 50%, and Craig-Hallum downgraded the stock to neutral, citing weak Taser performance and volatility from federal contract timing. Despite the sell-off, management emphasized that underlying demand remains strong, with CFO Joshua Isner stating, "the demand picture is still very, very strong."

The sharp sell-off in Axon shares reflects investor concerns about growth deceleration and margin pressure. However, the revenue miss was largely due to a timing issue rather than a structural problem. The delayed Federal Dedrone deployment is a matter of when, not if, the revenue is recognized. Moreover, the company's core business—body cameras, cloud services, and Taser—continues to grow, with connected devices revenue up 16.3%.

The guidance cut for free cash flow is also a temporary issue related to inventory build-up. Axon is investing in inventory to ensure product availability and supply chain resilience, which should support future growth. The company's recent introduction of the Taser Ion, its most flexible Taser device yet, could help rejuvenate Taser sales in the coming quarters.

Axon's strategic investments, such as the additional $1.2 billion in Skydio (bringing its stake to 37%), position it well in the emerging drone technology space. The company has a strong track record of growing revenue at around 30% annually, and it is on track to achieve that again this year. At a price-to-sales ratio of 7, the stock is now trading at a valuation that is attractive relative to its growth prospects.

While the market is focused on short-term headwinds, the long-term growth story remains intact. Axon's dominant position in law enforcement technology, recurring revenue from cloud services, and expansion into drones and counter-drone systems provide multiple avenues for future growth. The sell-off may be an overreaction, presenting a buying opportunity for patient investors.